Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 100

1.

Ipragliflozin Ameliorates Liver Damage in Non-alcoholic Fatty Liver Disease.

Miyake T, Yoshida S, Furukawa S, Sakai T, Tada F, Senba H, Yamamoto S, Koizumi Y, Yoshida O, Hirooka M, Kumagi T, Niiya T, Miyaoka H, Masanori A, Matsuura B, Hiasa Y.

Open Med (Wars). 2018 Sep 14;13:402-409. doi: 10.1515/med-2018-0059. eCollection 2018.

2.

Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes.

Takahashi K, Cho KY, Nakamura A, Miya A, Miyoshi A, Yamamoto C, Nomoto H, Niwa H, Takahashi K, Manda N, Kurihara Y, Aoki S, Ito YM, Atsumi T, Miyoshi H.

J Diabetes Investig. 2018 Aug 22. doi: 10.1111/jdi.12913. [Epub ahead of print]

3.

Long-Term Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: 104-Week Follow-up of an Open-Label Study.

Ito D, Inoue K, Sumita T, Hamaguchi K, Kaneko K, Yanagisawa M, Inukai K, Inoue I, Noda M, Shimada A.

J Clin Med Res. 2018 Sep;10(9):679-687. doi: 10.14740/jocmr3491w. Epub 2018 Jul 31.

4.

Effects of the SGLT2 inhibitor ipragliflozin on food intake, appetite-regulating hormones, and arteriovenous differences in postprandial glucose levels in type 2 diabetic rats.

Tahara A, Kondo Y, Takasu T, Tomiyama H.

Biomed Pharmacother. 2018 Sep;105:1033-1041. doi: 10.1016/j.biopha.2018.06.062. Epub 2018 Jun 19.

PMID:
30021338
5.

Ipragliflozin Add-on Therapy to a GLP-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes (AGATE): A 52-Week Open-Label Study.

Ishihara H, Yamaguchi S, Nakao I, Sakatani T.

Diabetes Ther. 2018 Jun 20. doi: 10.1007/s13300-018-0455-8. [Epub ahead of print]

6.

Tolerability and Efficacy of Ipragliflozin in The Management of Inadequately Controlled Type 2 Diabetes mellitus: A Systematic Review and Meta-analysis.

Elgebaly A, Abdelazeim N, Abdelazeim B, El Ashal G, Mattar O, Namous L, Nasreldin N.

Exp Clin Endocrinol Diabetes. 2018 Jun 18. doi: 10.1055/a-0579-7860. [Epub ahead of print]

PMID:
29913526
7.

Comparative study of the effects of ipragliflozin and sitagliptin on multiple metabolic variables in Japanese patients with type 2 diabetes: A multicentre, randomized, prospective, open-label, active-controlled study.

Tsurutani Y, Nakai K, Inoue K, Azuma K, Mukai S, Maruyama S, Iizuka T, Matsuzawa Y, Saito J, Omura M, Nishikawa T.

Diabetes Obes Metab. 2018 Nov;20(11):2675-2679. doi: 10.1111/dom.13421. Epub 2018 Jul 4.

PMID:
29893003
8.

Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial.

Han KA, Chon S, Chung CH, Lim S, Lee KW, Baik S, Jung CH, Kim DS, Park KS, Yoon KH, Lee IK, Cha BS, Sakatani T, Park S, Lee MK.

Diabetes Obes Metab. 2018 Oct;20(10):2408-2415. doi: 10.1111/dom.13394. Epub 2018 Jul 16.

PMID:
29862619
9.

Improved cardiometabolic risk factors in Japanese patients with type 2 diabetes treated with ipragliflozin: a pooled analysis of six randomized, placebo-controlled trials.

Kashiwagi A, Sakatani T, Nakamura I, Akiyama N, Kazuta K, Ueyama E, Takahashi H, Kosakai Y.

Endocr J. 2018 Jul 28;65(7):693-705. doi: 10.1507/endocrj.EJ17-0491. Epub 2018 May 29.

10.

Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).

Nomiyama T, Shimono D, Horikawa T, Fujimura Y, Ohsako T, Terawaki Y, Fukuda T, Motonaga R, Tanabe M, Yanase T; Collaborators of Fukuoka Study of Ipragliflozin (FUSION) trial.

Endocr J. 2018 Aug 27;65(8):859-867. doi: 10.1507/endocrj.EJ18-0022. Epub 2018 May 26.

11.

Protective Effect of Ipragliflozin on Pancreatic Islet Cells in Obese Type 2 Diabetic db/db Mice.

Takasu T, Takakura S.

Biol Pharm Bull. 2018;41(5):761-769. doi: 10.1248/bpb.b17-01007.

12.

Prevention of progression of diabetic nephropathy by the SGLT2 inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice.

Tahara A, Takasu T.

Eur J Pharmacol. 2018 Jul 5;830:68-75. doi: 10.1016/j.ejphar.2018.04.024. Epub 2018 Apr 25.

PMID:
29702076
13.

Improvement in the proinsulin/C-peptide ratio during treatment with ipragliflozin in Japanese patients with type 2 diabetes mellitus.

Takase T, Nakamura A, Yamamoto C, Atsumi T, Miyoshi H.

Expert Opin Pharmacother. 2018 May;19(7):631-632. doi: 10.1080/14656566.2018.1459258. Epub 2018 Apr 5. No abstract available.

PMID:
29591723
14.

Comprehensive renoprotective effects of ipragliflozin on early diabetic nephropathy in mice.

Kamezaki M, Kusaba T, Komaki K, Fushimura Y, Watanabe N, Ikeda K, Kitani T, Yamashita N, Uehara M, Kirita Y, Shiotsu Y, Sakai R, Fukuda T, Yamazaki M, Fukui M, Matoba S, Tamagaki K.

Sci Rep. 2018 Mar 5;8(1):4029. doi: 10.1038/s41598-018-22229-5.

15.

Long-term use of ipragliflozin improved cardiac sympathetic nerve activity in a patient with heart failure: A case report.

Kiuchi S, Hisatake S, Kabuki T, Fujii T, Oka T, Dobashi S, Hashimoto H, Ikeda T.

Drug Discov Ther. 2018 Mar 19;12(1):51-54. doi: 10.5582/ddt.2017.01069. Epub 2018 Feb 25.

16.

Antidiabetic effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed diets containing different carbohydrate contents.

Tahara A, Takasu T.

Life Sci. 2018 Mar 15;197:80-90. doi: 10.1016/j.lfs.2018.02.009. Epub 2018 Feb 6.

PMID:
29425766
17.

Safety and efficacy of ipragliflozin in elderly versus non-elderly Japanese patients with type 2 diabetes mellitus: a subgroup analysis of the STELLA-LONG TERM study.

Maegawa H, Tobe K, Tabuchi H, Nakamura I, Uno S.

Expert Opin Pharmacother. 2018 Mar;19(4):327-336. doi: 10.1080/14656566.2018.1434145. Epub 2018 Mar 5.

PMID:
29388470
18.

Effects of the SGLT2 inhibitor ipragliflozin on various diabetic symptoms and progression of overt nephropathy in type 2 diabetic mice.

Tahara A, Takasu T.

Naunyn Schmiedebergs Arch Pharmacol. 2018 Apr;391(4):395-406. doi: 10.1007/s00210-018-1469-5. Epub 2018 Jan 26.

PMID:
29374293
19.

Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high-fat diet.

Takagi S, Li J, Takagaki Y, Kitada M, Nitta K, Takasu T, Kanasaki K, Koya D.

J Diabetes Investig. 2018 Sep;9(5):1025-1032. doi: 10.1111/jdi.12802. Epub 2018 Mar 12.

20.

Effects of Ipragliflozin on Postprandial Glucose Metabolism and Gut Peptides in Type 2 Diabetes: A Pilot Study.

Ueno H, Nakazato H, Ebihara E, Noma K, Kawano T, Nagamine K, Sakoda H, Nakazato M.

Diabetes Ther. 2018 Feb;9(1):403-411. doi: 10.1007/s13300-018-0366-8. Epub 2018 Jan 10.

Supplemental Content

Loading ...
Support Center